---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031246"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:24:45.333150+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProPhase Labs Q3 net revenue $24.2M (+155% YoY), net income $1.0M vs loss, adj. EBITDA $6.3M record

## Summary
- Q3 2022 net revenue $24.2M, up 155% from $9.5M in Q3 2021; net income $1.0M ($0.06 EPS) vs net loss $4.0M ($0.26 loss).
- Adjusted EBITDA $6.3M (record for Q3) versus adjusted EBITDA loss of $1.3M in the prior-year quarter.
- Cash, cash equivalents & restricted cash $22.8M at Sep 30, 2022 vs $8.7M at Dec 31, 2021; working capital $53.6M.
- Signed MOU with G42 Healthcare for genomic sequencing/AI; entered two-year collaborative agreement with Dana-Farber for Linebacker-1 cancer co-therapy.

## SEC filing metadata
- accession: 0001493152-22-031246
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000149315222031246/0001493152-22-031246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000149315222031246/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031246
- JSON: https://secwatch.observer/filing/0001493152-22-031246.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031246.txt

## Key facts
- Earnings Releases
  ProPhase Labs, Inc. reported the third quarter ended September 30, 2022 results: revenue $24.2 million, net income $1.0 million, or $0.06 per share, EPS $0.06 per share.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $24.2 million
  - Net income: $1.0 million, or $0.06 per share
  - EPS: $0.06 per share
  - Result: reported results
  source text: Current Report on Form 8-K. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 ProPhase Labs Announces Record Third Quarter 2022 Financial Results Q3 2022 Net Revenues of $24.2 Million (a Q3 record); Up 155% Year-over-Year Q3 2022 Net Income of $1.0 Million versus a loss in Q3 2021 Q3 2022 adjusted EBITDA of $6.3 million (a Q3 record) versus a loss in Q3 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/868278/000149315222031246/0001493152-22-031246-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.